中华泌尿外科杂志
中華泌尿外科雜誌
중화비뇨외과잡지
CHINESE JOURNAL OF UROLOGY
2012年
12期
951-954
,共4页
袁建林%王亮%陈立军%张旭%潘进洪%叶林阳%肖序仁%邱建宏%张克勤%叶钢
袁建林%王亮%陳立軍%張旭%潘進洪%葉林暘%肖序仁%邱建宏%張剋勤%葉鋼
원건림%왕량%진립군%장욱%반진홍%협림양%초서인%구건굉%장극근%협강
癌,肾细胞%舒尼替尼%辅助治疗%高危肾癌
癌,腎細胞%舒尼替尼%輔助治療%高危腎癌
암,신세포%서니체니%보조치료%고위신암
Carcinoma,renal cell%Sunitinib%Adjuvant therapy%High-risk renal cell carcinoma
目的 评价高危肾细胞癌术后舒尼替尼辅助治疗的疗效与安全性. 方法 接受根治性肾切除术的肾癌患者60例,均经病理检查确诊为肾透明细胞癌.术后1个月开始口服舒尼替尼50 mg(用4周停2周方案)或37.5 mg每日连续给药的方案治疗,共3个周期. 结果 60例患者均可耐受舒尼替尼治疗,无因不良反应而中止治疗者.不良反应多为1～2度.其中中性粒细胞减少56.7％,其次为血小板减少53.3％、白细胞减少48.3％、手足综合征46.7％和高血压36.7％.3 ～4度不良反应血小板减少发生率为25.0％,其次为中性粒细胞减少(15.0％)、手足综合征(11.7％)、白细胞减少(8.3％).大多数不良反应于治疗后1～2个周期内发生,并于治疗停止后1个月左右减轻,无不可逆的不良反应发生.截至2012年4月5日,除1例死于与疾病无关的脑血管意外外,余59例未出现复发,6个月和9个月的无疾病复发生存率100％. 结论 高危肾癌患者术后舒尼替尼辅助治疗的骨髓抑制发生率少于晚期肾癌患者,但仍需较长期的进一步数据来证实.
目的 評價高危腎細胞癌術後舒尼替尼輔助治療的療效與安全性. 方法 接受根治性腎切除術的腎癌患者60例,均經病理檢查確診為腎透明細胞癌.術後1箇月開始口服舒尼替尼50 mg(用4週停2週方案)或37.5 mg每日連續給藥的方案治療,共3箇週期. 結果 60例患者均可耐受舒尼替尼治療,無因不良反應而中止治療者.不良反應多為1～2度.其中中性粒細胞減少56.7％,其次為血小闆減少53.3％、白細胞減少48.3％、手足綜閤徵46.7％和高血壓36.7％.3 ～4度不良反應血小闆減少髮生率為25.0％,其次為中性粒細胞減少(15.0％)、手足綜閤徵(11.7％)、白細胞減少(8.3％).大多數不良反應于治療後1～2箇週期內髮生,併于治療停止後1箇月左右減輕,無不可逆的不良反應髮生.截至2012年4月5日,除1例死于與疾病無關的腦血管意外外,餘59例未齣現複髮,6箇月和9箇月的無疾病複髮生存率100％. 結論 高危腎癌患者術後舒尼替尼輔助治療的骨髓抑製髮生率少于晚期腎癌患者,但仍需較長期的進一步數據來證實.
목적 평개고위신세포암술후서니체니보조치료적료효여안전성. 방법 접수근치성신절제술적신암환자60례,균경병리검사학진위신투명세포암.술후1개월개시구복서니체니50 mg(용4주정2주방안)혹37.5 mg매일련속급약적방안치료,공3개주기. 결과 60례환자균가내수서니체니치료,무인불량반응이중지치료자.불량반응다위1～2도.기중중성립세포감소56.7％,기차위혈소판감소53.3％、백세포감소48.3％、수족종합정46.7％화고혈압36.7％.3 ～4도불량반응혈소판감소발생솔위25.0％,기차위중성립세포감소(15.0％)、수족종합정(11.7％)、백세포감소(8.3％).대다수불량반응우치료후1～2개주기내발생,병우치료정지후1개월좌우감경,무불가역적불량반응발생.절지2012년4월5일,제1례사우여질병무관적뇌혈관의외외,여59례미출현복발,6개월화9개월적무질병복발생존솔100％. 결론 고위신암환자술후서니체니보조치료적골수억제발생솔소우만기신암환자,단잉수교장기적진일보수거래증실.
Objective To evaluate the efficacy and safety of sunitinib as post-operative adjuvant therapy in patients with high-risk renal cell carcinoma (RCC).Methods A total of 60 patients with resected,histologically confirmed clear cell RCC were enrolled in this study.Patients received orally sunitinib either at a dose of 50 mg on treatment schedule (once daily for 4 weeks followed by 2 weeks off) or at a dose of 37.5 mg once daily for three 6-week cycles from 1 month after surgery.Results All the 60 patients tolerated Sunitinib treatment well and no patient discontinued treatment due to adverse events.Most adverse events were grade Ⅰ to Ⅱ.The most frequently reported adverse events were neutropenia (56.7％),thrombocytopenia (53.3％),leucopenia (48.3％),hand-foot syndrome (46.7％) and hypertension (36.7％).The most frequently reported grade 3 or 4 toxicities were thrombocytopenia (25.0％),neutropenia (15.0％),hand-foot syndrome (11.7％) and leucopenia (8.3％).The majority of adverse events occurred within the first 1-2 cycles of sunitinib treatment,and was ameliorated 1 month after 3 cycles finished.No irreversible adverse event was observed.As of April 5,2012,no recurrence occurred in patients except one death due to cerebrovascular accident unrelated to treatment,with both 6-month and 9-month disease-free survival rate of 100％.Conclusions Myelosuppression occurred less frequently in high-risk RCC patients treated with sunitinib as operative adjuvant therapy than in advanced RCC patients,with a better benefit trend.However,long-term follow-up data are needed to further confirm the efficacy of sunitinib in the adjuvant setting.
